Citi raised the firm’s price target on Argenx (ARGX) to $1,124 from $1,041 and keeps a Buy rating on the shares. The firm left a meeting with management with more confidence in Argenx’s commercial potential. Citi’s U.S. neurologist survey points to continued expansion opportunities in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy for the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx removed from Best Ideas List at Wedbush
- Argenx: Strong Market Position and Growth Potential Justify Buy Rating
- Argenx price target raised to $925 from $830 at JPMorgan
- Promising Outlook for arGEN X: Robust Sales Projections and Strategic Expansion Drive Positive Risk-Reward Balance
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly